Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Annovis Bio, Inc. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, VAJDA, KRISTIN ANN, who is also designated as the busiest examiner for the portfolio. The prosecution is localized within 1 distinct art unit, reflecting a highly specific technical focus for this pending matter. This alignment of the pending matter with a single examiner and art unit indicates a highly focused prosecution effort.
With VAJDA, KRISTIN ANN responsible for the 1 pending office action, the company's immediate prosecution success depends entirely on the interactions within this single art unit. The busiest examiner is currently handling 1 pending office action, which simplifies the administrative tracking for this portfolio. Practitioners can focus their efforts on the specific requirements and examination style of the assigned individual. Because the workload is limited to 1 distinct art unit, the prosecution path is currently narrow and focused on the specific technical standards of that unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18420514 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | VAJDA, KRISTIN ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18420514 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18420514 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | VAJDA, KRISTIN ANN | 1622 | §112 | Non-Final OA | — | Pending | Jan 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial